









Markets
/
Stocks
/
nasdaq-rigl
/

Rigel Pharmaceuticals Inc

RIGL

34.150USD

+0.930+2.80%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

619.62MMarket Cap

5.39P/E TTM



Rigel Pharmaceuticals Inc

34.150

+0.930+2.80%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Rigel Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

Rigel Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 47.00.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Rigel Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

48 / 159

Overall Ranking

139 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Rigel Pharmaceuticals Inc Highlights

StrengthsRisks

Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 49.10% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 5.39, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 15.46M shares, decreasing 0.24% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 1.72K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.39.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

47.000

Target Price

+41.48%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Rigel Pharmaceuticals Inc is 8.78, ranking 37 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 69.46M, representing a year-over-year increase of 25.59%, while its net profit experienced a year-over-year increase of 124.62%.

Score

Industry at a Glance

Previous score

8.78

Change



Financials

9.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.81

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.40

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Rigel Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Rigel Pharmaceuticals Inc is 8.67, ranking 11 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 5.39, which is 355.26% below the recent high of 24.52 and 2167.45% above the recent low of -111.36.

Score

Industry at a Glance

Previous score

8.67

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 48/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Rigel Pharmaceuticals Inc is 7.67, ranking 98 out of 159 in the Pharmaceuticals industry. The average price target is 42.00, with a high of 69.00 and a low of 24.00.

Score

Industry at a Glance

Previous score

7.67

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 6 analysts

Buy

Current Rating

47.000

Target Price

+41.48%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Rigel Pharmaceuticals Inc

RIGL

Apple Inc

AAPL

Ge Vernova Inc

GEV

Tapestry Inc

TPR

FMC Corp

FMC

Avantor Inc

AVTR

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Rigel Pharmaceuticals Inc is 6.75, ranking 110 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 41.92 and the support level at 29.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.62

Change

0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.364

Sell

RSI(14)

37.212

Neutral

STOCH(KDJ)(9,3,3)

20.500

Neutral

ATR(14)

1.618

High Vlolatility

CCI(14)

-121.107

Sell

Williams %R

80.496

Oversold

TRIX(12,20)

-0.778

Sell

StochRSI(14)

53.200

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

34.906

Sell

MA10

35.405

Sell

MA20

36.803

Sell

MA50

41.303

Sell

MA100

37.186

Sell

MA200

31.002

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Rigel Pharmaceuticals Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 85.19%, representing a quarter-over-quarter increase of 5.74%. The largest institutional shareholder is The Vanguard, holding a total of 1.04M shares, representing 5.72% of shares outstanding, with 0.55% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

1.48M

+5.38%

The Vanguard Group, Inc.

Star Investors

1.04M

-0.93%

Armistice Capital LLC

724.00K

-54.75%

Acadian Asset Management LLC

685.72K

+10.07%

Marshall Wace LLP

601.33K

+62.98%

Capitolis Liquid Global Markets LLC

591.55K

State Street Investment Management (US)

554.32K

-7.64%

Goldman Sachs Asset Management, L.P.

488.26K

+326.10%

Renaissance Technologies LLC

Star Investors

474.21K

+100.56%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Rigel Pharmaceuticals Inc is 4.47, ranking 89 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.11. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.